Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc.
Your view on CATX
Overview
What the company does, where it operates, and who runs it.
About Perspective Therapeutics, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Johan M. Spoor
- Headquarters
- 350 Hills Street, Seattle, WA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Johan M. Spoor
- Headquarters
- 350 Hills Street, Seattle, WA, US
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.
The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Perspective Therapeutics, Inc., and the rating behind it. CATX last traded at $2.81; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Perspective Therapeutics, Inc.. Starting points for Perspective Therapeutics, Inc.: EPS -$1.58, beta 1.80 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Perspective Therapeutics, Inc.. Perspective Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Perspective Therapeutics, Inc.. Trailing twelve-month EPS for Perspective Therapeutics, Inc. stands at -$1.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Perspective Therapeutics, Inc.. Perspective Therapeutics, Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Perspective Therapeutics, Inc. valued side by side against its closest peers. Perspective Therapeutics, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Perspective Therapeutics, Inc., and how their positions are changing. At a $320.5M market value, institutional positions materially move Perspective Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Perspective Therapeutics, Inc. executives and directors. Shares of Perspective Therapeutics, Inc. have traded between $1.60 and $6.87 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Perspective Therapeutics, Inc.. Perspective Therapeutics, Inc. is a $320.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Perspective Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Perspective Therapeutics, Inc.. Coverage tracks Perspective Therapeutics, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.